Yamamoto, Noboru

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Seto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., et al. (2014) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 750

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Lala, M., Li, T. R., de Alwis, D. P., Sinha, V., Mayawala, K., Yamamoto, N., Siu, L. L., Chartash, E., Aboshady, H., & Jain, L. (2020) · European Journal of Cancer

Cancer Immunotherapy and BiomarkersPharmaceutical studies and practices

Cited by 165

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

Harding, J. J., Moreno, V., Bang, Y.-J., Hong, M. H., Patnaik, A., Trigo, J., Szpurka, A. M., Yamamoto, N., Doi, T., Fu, S., et al. (2021) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 161

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science

Thyroid Disorders and TreatmentsCancer Immunotherapy and Biomarkers

Cited by 158

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer

Heymach, J. V., Ruiter, G., Ahn, M.-J., Girard, N., Smit, E. F., Planchard, D., Wu, Y.-L., Cho, B. C., Yamamoto, N., Sabari, J. K., et al. (2025) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 118

The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study

LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., et al. (2023) · Cancer Discovery

Cancer-related Molecular PathwaysPI3K/AKT/mTOR signaling in cancer

Cited by 101

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

Ou, S.-H. I., Fujiwara, Y., Shaw, A. T., Yamamoto, N., Nakagawa, K., Fan, F., Hao, Y., Gao, Y., Jänne, P. A., & Seto, T. (2021) · JTO Clinical and Research Reports

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 40

Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors

Takahashi, S., Karayama, M., Takahashi, M., Watanabe, J., Minami, H., Yamamoto, N., Kinoshita, I., Lin, C.-C., Im, Y.-H., Achiwa, I., et al. (2021) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchPharmacogenetics and Drug Metabolism

Cited by 37

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC).

Cassier, P. A., Dooms, C. A., Gazzah, A., Felip, E., Steeghs, N., Rohrberg, K. S., De Braud, F. G., Solomon, B. J., Schuler, M. H., Tan, D. S.-W., et al. (2023) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 35

Implementing Generative Artificial Intelligence in Precision Oncology: Safety, Governance, and Significance

Hamamoto, R., Koyama, T., Takahashi, S., Yasuda, T., Kobayashi, K., Akagi, Y., Kouno, N., Sudo, K., Hirata, M., Sunami, K., et al. (2026) · Journal of Hematology & Oncology

Artificial Intelligence in Healthcare and EducationMachine Learning in Healthcare

Cited by 8

1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)

Kondo, S., Yan, D., Ganju, V., Richardson, G., Hou, X., Shan, J., Liu, X., Zhang, Y., Xie, X., Xiang, Z., et al. (2023) · Annals of Oncology

Pancreatic and Hepatic Oncology ResearchProtein Kinase Regulation and GTPase Signaling

Cited by 6

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

Yamamoto, N., Yan, D., Ganju, V., Hou, X., Pan, H., Shan, J., Wang, L., Kim, S.-W., Richardson, G., Sanborn, R. E., et al. (2026) · British Journal of Cancer

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 5